<DOC>
	<DOCNO>NCT00017992</DOCNO>
	<brief_summary>The purpose study see emtricitabine safe child infect HIV determine best dose .</brief_summary>
	<brief_title>Emtricitabine Given Once A Day With Other Anti-HIV Drugs Children With HIV</brief_title>
	<detailed_description>Children place 1 4 treatment group base age : Group 1 , 3 month 24 month ; Group 2 , 25 month 6 year ; Group 3 , 7 year 12 year ; Group 4 , 13 year 17 year . They receive baseline evaluation . Antiretroviral-naive patient receive emtricitabine plus stavudine plus lopinavir/ritonavir . Antiretroviral-experienced patient replace lamivudine emtricitabine . Patients return clinic follow-up visit Weeks 2 4 every 4 week Week 48 . Safety evaluate use adverse event , review every clinic visit . Clinical laboratory data full-profile pharmacokinetics emtricitabine evaluate visit . After Week 48 study evaluation complete , individual patient may continue receive study medication ( provide sponsor ) commercially available , certain criterion meet .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Inclusion Criteria Children may eligible study : Are least 3 month old old 17 year age . This age child need time begin study . Are HIV positive . Weigh 5.5 pound . A newborn child must reach least 38 week gestation . Have take antiHIV drug . Those must viral load 5,000 500,000 copies/ml screening . Those must take antiHIV drug , include lamivudine , least 3 month viral load 400 copies/ml screening . Have CD4 count 200 cells/mm3 . Have write consent parent guardian . Are willing use effective birth control study 1 month last dose emtricitabine , sexually active . Exclusion Criteria Children eligible study : Are pregnant breastfeeding . Can follow visit dose schedule available 1 year . Have take experimental drug vaccine ( except emivirine experimental form approve drug ) within 30 day study start . Have nerve damage arm leg . Have trouble eat take drug . Have serious diarrhea within 30 day study entry . Have serious illness within 30 day study screen . Any treatment must finish 14 day study entry . Have AIDSrelated ( opportunistic ) disease within 12 month screen . Are treated tuberculosis . Have pancreatitis . Require certain drug .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ABT 378</keyword>
	<keyword>emtricitabine</keyword>
</DOC>